An interventional study of Brain Health Pro in Vision and Hearing Loss, Vision Impairment and Hearing Impairment, sponsored by Université de Montréal. Not yet recruiting at 1 site in Canada. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Université de Montréal · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Vision Disorders with a site in Canada — 6 open to participants now, 9 under way, 2 of them phase 3. Vision Disorders · Canada.
Among the 33 studies in Vision Disorders with a site in Canada, this one is the 6th largest by planned enrollment of the 31 interventional ones that give a count, is the only one that started in 2026, is one of 12 with no phase, and was the 33rd registered.
361 studies on the registry are indexed under Vision Disorders; 85 are open to participants now.
Browse Vision Disorders studies →6 of the 33 studies in Vision Disorders with a site in Canada are open now. Recruiting first, the newest first:
Laboratoires Thea · Sites in Canada, United States, Australia and 7 more countries
Ages 6+
University of Alberta · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18–90
University Health Network, Toronto · Sites in Canada
Ages 18–90
University Health Network, Toronto · Sites in Canada
Ages 25+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 46 Vision Disorders studies recruiting now, 21 (46%) set no upper age limit and 16 (35%) stop at 75 or younger; 18 take children under 18; 13 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 13 · Phase 4 1
First in 2007; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 75 across 245 interventional studies indexed under Vision Disorders.
Median enrollment 40 across the 31 interventional studies, 1,352 across the 2 observational. Of the 18 that completed or were terminated, 11 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 33 have an industry lead sponsor. The 10 most frequent:
Université de Montréal is the lead sponsor of 98 studies on the registry; 11 are open to participants now.
Université de Montréal has 1 study filed under Vision Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Vision Disorders with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06891443Phase 3Laboratoires TheaStudy to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) | 2027-11 |
| NCT06075147BayerThe SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 33 studies in Vision Disorders with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to learn about the outcomes, usability, and accessibility of the online Brain Health Pro program for older adults with hearing difficulties, vision difficulties, or both. Brain Health Pro (BHPro) provides information and practical suggestions about ways people may support their brain health and lower their risk of dementia.
The main questions this study aims to answer are:
Does participants' knowledge about dementia and its risk factors change after using Brain Health Pro? How usable and accessible is Brain Health Pro for people with hearing or vision difficulties? What factors help or make it more difficult for participants to use and complete the program?
About 300 adults aged 55 years and older with hearing difficulties, vision difficulties, or both will take part in the study. Participants will:
Use the online Brain Health Pro program for six months. Complete online questionnaires before starting the program and again at 3 and 6 months.
Share their experiences using the program, including any difficulties related to hearing, vision, or using the online program.
Researchers will also look at whether participants make changes in health behaviours that may support brain health and whether they feel more confident about making these changes.
SENSE-Brain Health Pro (SENSE-BHPro) is a prospective, multi-site study using a one-group pretest-post-test design with an embedded mixed-methods process evaluation. The study evaluates the accessibility, acceptability, usability, and outcomes associated with participation in the web-based Brain Health Pro (BHPro) program among older adults with self-reported hearing and/or vision difficulties.
Hearing and vision difficulties are common in older adulthood and are associated with increased risk of cognitive decline and dementia. Digital dementia prevention programs have the potential to reach large numbers of older adults; however, sensory difficulties may create barriers to accessing and engaging with digitally delivered interventions. The original BHPro program was not specifically implemented in a population selected for hearing and/or vision difficulties, and its accessibility and usability in this population have not been systematically evaluated. SENSE-BHPro addresses this gap by examining both intervention outcomes and the accessibility and implementation of BHPro for older adults with sensory difficulties.
Approximately 300 community-dwelling adults aged 55 years and older with self-reported hearing difficulties, vision difficulties, or combined hearing and vision difficulties will be recruited across Canada. Participants will have no self-reported diagnosis of dementia. Individuals who are cognitively unimpaired, report subjective cognitive concerns, or have mild cognitive impairment may participate if they otherwise meet the study eligibility criteria.
Participants will complete the BHPro program, a web-based multidomain psychoeducational dementia risk-reduction program. BHPro provides individualized feedback on potentially modifiable dementia risk factors and evidence-based educational content addressing lifestyle, vascular, psychosocial, and cognitive health domains. Participants receive a personalized risk profile, practical recommendations, and structured guidance intended to support goal setting and self-management. The core intervention is delivered progressively through structured online modules over six months.
Assessments will occur at screening, baseline, Month 3, and Month 6. The primary outcome is change in knowledge about Alzheimer's disease from baseline to Month 6, assessed using the Alzheimer's Disease Knowledge Scale (ADKS). Secondary and exploratory evaluations include self-efficacy, uptake of risk-reducing behaviours, psychological well-being, lifestyle factors, usability, acceptability, accessibility, and engagement with the intervention.
Accessibility is a central component of the study. Participants will receive information and guidance regarding accessibility features available within BHPro and on their own devices, such as captions, text magnification, contrast settings, and audio adjustments, as appropriate. Use of accessibility features and assistive technologies will be documented to better understand how participants with different sensory profiles engage with the digital intervention.
Outcomes and implementation experiences will also be examined across three sensory subgroups: participants with hearing difficulties, vision difficulties, and combined hearing and vision difficulties. The study will also examine individual characteristics that may influence engagement and outcomes, including sensory profile and severity, demographic characteristics, cognitive status, and the perceived functional effects of sensory difficulties.
An embedded process evaluation will examine recruitment pathways, participant engagement, adherence patterns, accessibility needs, barriers and facilitators to participation, and implementation considerations relevant to integrating BHPro within primary care and community-based settings serving older adults with hearing and/or vision difficulties. Findings are intended to inform future adaptations and implementation of accessible digital dementia risk-reduction programs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will use the Brain Health Pro (BHPro) web-based program for six months. BHPro provides personalized information and recommendations about potentially modifiable dementia risk factors and supports participants in making health and lifestyle changes that may promote brain health.
Behavioral: Brain Health Pro
Brain Health Pro (BHPro) is a web-based educational program designed to support dementia risk reduction. Participants receive personalized information about potentially modifiable dementia risk factors and evidence-based recommendations related to lifestyle, vascular, psychosocial, and cognitive health. The program supports goal setting and behaviour change through structured online modules delivered progressively over six months.
Change in Knowledge About Alzheimer's Disease Assessed Using the Alzheimer's Disease Knowledge Scale (ADKS)
Knowledge about Alzheimer's disease will be assessed using the Alzheimer's Disease Knowledge Scale (ADKS). The ADKS is a 30-item questionnaire with true/false response options that assesses knowledge about Alzheimer's disease across several domains. Each correct response receives one point, producing a total score ranging from 0 to 30. Higher scores indicate greater knowledge about Alzheimer's disease. Change in ADKS total score from baseline to Month 6 will be evaluated.
Time frame: Baseline to 6 months
Change in Self-Efficacy Assessed Using the General Self-Efficacy Scale (GSE)
Self-efficacy will be assessed using the General Self-Efficacy Scale (GSE), a 10-item questionnaire measuring perceived ability to cope with difficult situations and achieve goals. Each item is rated on a 4-point scale. Item scores are summed to produce a total score ranging from 10 to 40, with higher scores indicating greater perceived self-efficacy. Change in GSE total score from baseline to Month 3 and Month 6 will be evaluated.
Time frame: Baseline to Month 3 and Month 6
Usability of Brain Health Pro Assessed Using the Adapted System Usability Scale (SUS)
Usability will be assessed using the System Usability Scale (SUS), adapted for SENSE-Brain Health Pro. The adapted questionnaire includes items assessing frequency of website use and perceived usability, including ease of use, navigation, complexity, consistency, confidence, need for technical assistance, and ease of learning. Usability items are rated on a 5-point scale from strongly disagree to strongly agree. Additional study-specific items assess accessibility and are reported separately as an accessibility outcome.
Time frame: 3 months and 6 months
Acceptability of Brain Health Pro Assessed Using the Adapted Technology Acceptance Model (TAM) Questionnaire
Acceptability will be assessed using a 29-item Technology Acceptance Model (TAM) Questionnaire adapted for SENSE-Brain Health Pro. The questionnaire includes 26 structured items assessing perceived usefulness, communication, everyday benefits, website experience, and accessibility experience. Structured items are rated on a 7-point scale from strongly disagree to strongly agree. Three open-ended questions assess helpful accessibility features, suggested accessibility improvements, and barriers experienced while using Brain Health Pro.
Time frame: 3 months and 6 months
Perceived Dementia Risk and Risk-Reduction Behaviours Assessed Using PRISM-PC
Participants' perceptions of dementia risk and engagement in dementia risk-reduction behaviours will be assessed using Sections B and D of the Perceptions Regarding Investigational Screening for Memory in Primary Care (PRISM-PC) questionnaire.
Time frame: 3 months and 6 months
Accessibility Accommodations and Experiences With Brain Health Pro
Accessibility accommodations will be assessed using the SENSE-BHPro Accessibility Accommodations Questionnaire. The questionnaire documents vision-related accommodations, hearing-related accommodations, computer accessibility settings, assistance received from others, and participants' perceived usefulness of the accommodations used. Additional comments about accessibility accommodations may also be provided.
Time frame: Baseline, 3 months and 6 months
Barriers and Facilitators to Using Brain Health Pro
Barriers and facilitators will be assessed using the SENSE-BHPro Accessibility Barriers and Facilitators Questionnaire. Structured items assess ease of access and navigation, readability, audio accessibility, visual presentation, compatibility with assistive technologies, specific barriers and facilitators, and overall satisfaction. Agreement items use a 5-point scale from strongly disagree to strongly agree. Open-ended questions ask participants to describe their main accessibility barrier, what helped them most, and recommended improvements.
Time frame: 3 months and 6 months
Plan to share: No — Individual participant data will not be shared due to participant privacy and confidentiality considerations and because data sharing with external researchers is not included in the current study protocol and consent process.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Apr 2028, 18 months later.
Of 84 non-industry interventional studies with no phase under Vision Disorders, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 51. This study's planned 18 months is below that.
Counting every sponsor, half of 94 studies reached it within 24 months; a quarter within 6 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Université de Montréal